| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 5,430,757 | 8,505,229 | ||
| General and administrative | 2,570,375 | 1,663,503 | ||
| Loss from operations | -8,001,132 | -10,168,732 | ||
| Interest income | 788,694 | 872,038 | ||
| Interest expense | 475,903 | 470,618 | ||
| Total other income, net | 312,791 | 401,420 | ||
| Net loss | -7,688,341 | -9,767,312 | ||
| Earnings per share, basic | -0.13 | -0.16 | ||
| Earnings per share, diluted | -0.13 | -0.16 | ||
| Weighted average number of shares outstanding, basic | 60,126,850 | 60,045,530 | ||
| Weighted average number of shares outstanding, diluted | 60,126,850 | 60,045,530 | ||
Aldeyra Therapeutics, Inc. (ALDX)
Aldeyra Therapeutics, Inc. (ALDX)